Regulation of lactate production through p53/β-enolase axis contributes to statin-associated muscle symptoms

Weintraub, 2017, Perspective on trends in statin use, JAMA Cardiol, 2, 11, 10.1001/jamacardio.2016.4710 Newman Connie, 2019, Statin safety and associated adverse events: a scientific statement from the American Heart Association, Arterioscler. Thromb. Vasc. Biol., 39, e38 Serban, 2017, Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction, J Am Coll Cardiol, 69, 1386, 10.1016/j.jacc.2016.12.036 Backes, 2017, Statin-associated muscle symptoms-managing the highly intolerant, J Clin Lipidol, 11, 24, 10.1016/j.jacl.2017.01.006 Rosenson, 2017, Optimizing cholesterol treatment in patients with muscle complaints, J Am Coll Cardiol, 70, 1290, 10.1016/j.jacc.2017.07.752 Immke, 2001, Lactate enhances the acid-sensing Na+ channel on ischemia-sensing neurons, Nat Neurosci, 4, 869, 10.1038/nn0901-869 Salvemini, 2011, Roles of reactive oxygen and nitrogen species in pain, Free Radic. Biol. Med., 51, 951, 10.1016/j.freeradbiomed.2011.01.026 Neale, 2004, Statin precipitated lactic acidosis?, J Clin Pathol, 57, 989, 10.1136/jcp.2004.015958 Goli, 2002, Simvastatin-induced lactic acidosis: a rare adverse reaction?, Clin. Pharmacol. Ther., 72, 461, 10.1067/mcp.2002.127943 De Pinieux, 1996, Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio, Br J Clin Pharmacol, 42, 333, 10.1046/j.1365-2125.1996.04178.x Limprasertkul, 2012, Statin therapy depresses fat metabolism in older individuals, J Am Coll Nutr, 31, 32, 10.1080/07315724.2012.10720006 Seachrist, 2005, Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity, Toxicol. Sci., 88, 551, 10.1093/toxsci/kfi305 El-Ganainy, 2017, Rosuvastatin safety: an experimental study of myotoxic effects and mitochondrial alterations in rats, Toxicol Lett, 265, 23, 10.1016/j.toxlet.2016.10.017 El-Ganainy, 2016, Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model, Toxicology., 359-360, 29, 10.1016/j.tox.2016.06.015 Song, 2018, Trimetazidine restores the positive adaptation to exercise training by mitigating statin-induced skeletal muscle injury, J Cachexia Sarcopenia Muscle, 9, 106, 10.1002/jcsm.12250 Delliaux, 2006, Effect of long-term atorvastatin treatment on the electrophysiological and mechanical functions of muscle, Int J Clin Pharmacol Ther, 44, 251, 10.5414/CPP44251 Galtier, 2012, Effect of a high dose of simvastatin on muscle mitochondrial metabolism and calcium signaling in healthy volunteers, Toxicol Appl Pharmacol, 263, 281, 10.1016/j.taap.2012.06.020 Vaughan, 2013, Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis, Eur J Pharmacol, 711, 1, 10.1016/j.ejphar.2013.04.009 Piette, 2016, A short-term statin treatment changes the contractile properties of fast-twitch skeletal muscles, BMC Musculoskelet Disord, 17, 449, 10.1186/s12891-016-1306-2 Jung, 2004, Effect of medicinal plant extracts on forced swimming capacity in mice, J Ethnopharmacol, 93, 75, 10.1016/j.jep.2004.03.022 Godar, 2008, Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression, Cell., 134, 62, 10.1016/j.cell.2008.06.006 Muraki, 2012, Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance, J Appl Physiol, 113, 479, 10.1152/japplphysiol.01362.2011 Bouitbir, 2011, Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress, J Appl Physiol, 111, 1477, 10.1152/japplphysiol.00107.2011 Rosenson, 2014, The National Lipid Association's muscle safety expert P. An assessment by the statin muscle safety task force: 2014 update, J Clin Lipidol, 8, S58, 10.1016/j.jacl.2014.03.004 Apostolopoulou, 2015, The role of mitochondria in statin-induced myopathy, Eur J Clin Invest, 45, 745, 10.1111/eci.12461 Sung, 2010, Mitochondrial respiration protects against oxygen-associated DNA damage, Nat Commun, 1, 5, 10.1038/ncomms1003 Ibi, 1983, Immunohistochemical demonstration of beta-enolase in human skeletal muscle, Muscle Nerve, 6, 661, 10.1002/mus.880060907 Morimoto, 2011, Atorvastatin prevents ischemic limb loss in type 2 diabetes: role of p53, J Atheroscler Thromb, 18, 200, 10.5551/jat.6437 Kruiswijk, 2015, p53 in survival, death and metabolic health: a lifeguard with a licence to kill, Nat Rev Mol Cell Biol, 16, 393, 10.1038/nrm4007 Paajarvi, 2005, HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage, FASEB J, 19, 476, 10.1096/fj.04-2745fje Johnson, 2001, Transcriptional repression by p53 through direct binding to a novel DNA element, J Biol Chem, 276, 27716, 10.1074/jbc.C100121200 James, 2017, Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1, Pharmacol Ther, 170, 166, 10.1016/j.pharmthera.2016.10.018 Hoshino, 2015, Effects of decreased lactate accumulation after dichloroacetate administration on exercise training-induced mitochondrial adaptations in mouse skeletal muscle, Physiol Rep, 3, 10.14814/phy2.12555 Abd, 2011, Statin-induced myopathy: a review and update, Expert Opin Drug Saf, 10, 373, 10.1517/14740338.2011.540568 Joy, 2009, Narrative review: statin-related myopathy, Ann Intern Med, 150, 858, 10.7326/0003-4819-150-12-200906160-00009 Souich, 2017, Myotoxicity of statins: mechanism of action, Pharmacol Ther, 175, 1, 10.1016/j.pharmthera.2017.02.029 Schaefer, 2004, Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats, Toxicol Appl Pharmacol, 194, 10, 10.1016/j.taap.2003.08.013 Tay, 2008, Myotoxicity of lipid-lowering agents in a teenager with MELAS mutation, Pediatr Neurol, 39, 426, 10.1016/j.pediatrneurol.2008.09.002 Hou, 2017, Histopathologic and biochemical evidence for mitochondrial disease among 279 patients with severe statin myopathy, J. Neuromuscul. Dis., 4, 77, 10.3233/JND-160184 Nakahara, 1998, Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study, Toxicol Appl Pharmacol, 152, 99, 10.1006/taap.1998.8491 Meador, 2010, Statin-associated myopathy and its exacerbation with exercise, Muscle Nerve, 42, 469, 10.1002/mus.21817 Westwood, 2008, Rosuvastatin: characterization of induced myopathy in the rat, Toxicol Pathol, 36, 345, 10.1177/0192623307311412 Collins, 2016, Interpretation of the evidence for the efficacy and safety of statin therapy, Lancet (London, England), 388, 2532, 10.1016/S0140-6736(16)31357-5 Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, Aetiology and management, Eur Heart J, 36, 1012, 10.1093/eurheartj/ehv043 Beyfuss, 2018, A systematic review of p53 regulation of oxidative stress in skeletal muscle, Redox Rep., 23, 100, 10.1080/13510002.2017.1416773 Matoba, 2006, p53 regulates mitochondrial respiration, Science., 312, 1650, 10.1126/science.1126863 Park, 2009, p53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content, Circ Res, 105, 10.1161/CIRCRESAHA.109.205310 Comi, 2001, Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis, Ann Neurol, 50, 202, 10.1002/ana.1095 Musumeci, 2014, Recurrent rhabdomyolysis due to muscle beta-enolase deficiency: very rare or underestimated?, J Neurol, 261, 2424, 10.1007/s00415-014-7512-7 Howlett, 1999, Effects of dichloroacetate infusion on human skeletal muscle metabolism at the onset of exercise, Am. J. Physiol. Endocrinol. Metab., 277, E18, 10.1152/ajpendo.1999.277.1.E18 Mallinson, 2012, Pharmacological activation of the pyruvate dehydrogenase complex reduces statin-mediated upregulation of FOXO gene targets and protects against statin myopathy in rodents, J Physiol, 590, 6389, 10.1113/jphysiol.2012.238022